| abstract |
The present invention is generally a CRF-1 receptor antagonist and is of Formula I or Formula II, wherein R 3 is optionally substituted aryl or heteroaryl, and R 1 and R 2 are Or the individual isomers, racemic mixtures or non-racemic mixtures of isomers or pharmaceutically acceptable salts thereof. The invention further relates to methods for producing such compounds, pharmaceutical compositions containing such compounds, and methods for their use as therapeutic agents. |